A novel recombinant vaccine against Cryptococcus.

一种针对隐球菌的新型重组疫苗。

• 批准号: 6841870
• 负责人: Claude P Selitrennikoff
• 金额: $ 10万
• 依托单位: MYCOLOGICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6841870
• 关键词: Cryptococcus neoformans; Saccharomyces cerevisiae; antigens; biotechnology; cryptococcosis; fungal genetics; fungal proteins; fungal vaccines; gene expression; genetic manipulation; laboratory mouse; recombinant DNA; vaccine development; vaccine evaluation; vector vaccine

DESCRIPTION (provided by applicant): Cryptococcus neoformans is an encapsulated pathogenic yeast that causes pulmonary infections and meningoencephalitis in humans and other animals. During the last 20 years, there has been a dramatic increase in the incidence of cryptococcosis throughout the world that mirrors the increase in not only HIV infections, but also in the growing number of immuno compromised patients. Loss of CD4+ T cells predisposes patients to progressive infection with C. neoformans--this emphasizes the role of cell mediated immunity in host resistance. Our long-term corporate goals are to discover new drugs for the treatment of fungal diseases and to develop vaccines against a number of human pathogenic fungi. In this Phase I STTR proposal, we plan to develop a safe and effective vaccine against C. neoformans. We will use a novel antigen delivery system and test a number of C. neoformans proteins as vaccine candidates. We will accomplish this in two specific aims: Specific Aim One: Engineer yeast cells to express each of five C. neoformans proteins using recombinant DNA technology. Specific Aim Two: Test the in vivo efficacy of each vaccine formulation to protect vaccinated animals against a challenge of C. neoformans. This work will be a prelude to work in Phase II that will include detailed testing for in vivo efficacy and safety of each vaccine candidate. Ultimately, the Phase I, Phase II and Phase lll research will lead to the development of a vaccine against C. neoformans

描述（由申请人提供）：新型隐球菌是一种包囊致病酵母，可引起人类和其他动物的肺部感染和脑膜脑炎。在过去的20年中，隐球菌病的发病率在全世界范围内急剧增加，这不仅反映了HIV感染的增加，而且反映了越来越多的免疫受损患者。CD 4 + T细胞的丢失使患者易于进行性感染C。新生儿-这强调了细胞介导的免疫在宿主抵抗中的作用。 我们的长期企业目标是发现治疗真菌疾病的新药，并开发针对多种人类致病真菌的疫苗。在第一阶段的STTR提案中，我们计划开发一种安全有效的C。新人类我们将使用一种新的抗原输送系统，并测试了一些C。作为疫苗候选物的新型人蛋白质。我们将通过两个具体目标实现这一目标： 具体目标一：工程酵母细胞表达的五个C。利用重组DNA技术， 具体目标二：检测每种疫苗制剂保护接种动物免受C.新人类 这项工作将是第二阶段工作的前奏，第二阶段工作将包括对每种候选疫苗的体内功效和安全性的详细测试。最终，I期、II期和III期研究将导致针对C的疫苗的开发。新生